Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same
CA 2245702 C · Owner: Rosenberg, Steven A. · Inventors: Rosenberg, Steven A.; Wang, Rong-Fu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention discloses that the normal melanogenic gene gp75 gene, encodes a gene product, a 24 amino acid peptide of ORF3 which is processed to , an antigenic cancer peptide recognized by T lymphocytes. The cancer peptide of the invention derived from ORF3 is recognized by cancer antigen specific T lymphocytes as a tumor rejection antigen. The present invention relates to the identification of a second tumor antigen recognized by an HLA-A31 restricted CTL clone derived from the TIL586 cell line. This antigen derived from the TRP- 2 protein tumor antigen and peptides thereof are capable of sensitizing target cells for lysis by a CTL clone at 1 nM peptide concentration. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 6, 1997 and granted October 4, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 6, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 6, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.